Progenity Launches First Commercially Available, Custom-Designed, Noninvasive Prenatal Test for Monogenic Diseases

SAN DIEGO–(BUSINESS WIRE)–Progenity, Inc., a privately held biotechnology company, announced today the launch of the Resura? Prenatal Test for Monogenic Disease, the first of its kind, commercially available, customizable, noninvasive prenatal test (NIPT) for single-gene disorders. This novel test broadens expectant parents? prenatal testing options to include a safe, noninvasive test tailored to their family?s risk for a specific genetic disease. In addition to this launch, Progenity announc